Leading Manufacturers in the Surgical Generators Market Contribute 45% Revenue Share

The global surgical generators market is estimated to hit the US$ 421.5 Million cap in 2019, expanding at a moderate year-on-year growth of 3.2 percent, during the same period. As per a recent market study by Future Market Insights, the global market for surgical generators is expected to represent an absolute dollar opportunity of US$ 161.65 Million, through the forecast period considering in the study, 2018-2028. Electrosurgical Radiofrequency (RF) generators, in terms of product type, are expected to pump maximum revenue into the global surgical generators market, holding a market share of approximately 49.4 percent. However, Argon Plasma Coagulation generators have shown significant adoption in recent years, as per the study, translating into a substantial market share in the coming years. Its application in haemostasis, tissue devitalization, tissue reduction, and for rapid surgical ablation solutions, using ultra precision are some key factors driving the Argon Plasma Coagulation generators segment, according to the study.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-663

FMI predicts moderately growing demand for surgical generators, considering:

• Increased technological innovations aimed at providing efficient electrosurgery and associated deices. Moreover, operating rooms have evolved substantially, in the recent years, mostly equipped with technologies offering high efficiency and productivity.
• Compatibility capabilities offered by new-age surgical generation, with various ablation devices. Additionally, advancements in surgical generators have changed the minimal invasive surgeries (MIS) landscape.
• Technologically advanced electrosurgical RF generators and ultrasonic generators have the ability to handle input variations for ablation devices and cautery, while also demonstrating the effectiveness, safety, accuracy of electrosurgical devices.
• Furthermore, deployment of low-cost ablation devices versus those required in RF-based ablation techniques including bipolar and ultrasonic ablation device, have significantly reduced the maintenance and repair costs, thereby further reducing the cost of surgical generators.
• Growing demand for plastic and cosmetic surgeries—all executed using various types of electrosurgical devices.
• Moreover, most modern surgeries require devices that provide energy to tissue to perform desired task.
• Growth of ambulatory surgical centers (ASCs) surgeries is considered a major factor for increased sales of surgical generators. Technologically advancements and market consolidation have immensely supported ASCs—now carrying out critical procedures including maxillofacial, hip, spine and laparoscopic surgeries.

“However, given the complexities relating to surgical generators in operating rooms, there are some critical market restrainers that we have studies in the recent report on surgical generators. Mostly importantly, lack of skill and training of operating electrosurgical devices along with complications in electrosurgery and potential risks of burns, are the key market inhibitors, considering that the modern day operating rooms and procedure suites are sophisticated computer-driven control centers of highly complex “point-of-care” delivery. Unfamiliarity with the basis functioning of such devices could prove fatal, in the form of Operating Room (OR) fires. Moreover, complications of electrosurgery can occur in form of combustible gases explosions, accidental burns, interference with pacemakers and monitors, and infection transmission”, explained a senior analysts from the healthcare domain, while listing out the reasons for a slow-moving surgical generators market.

Surgical Generators Market Showcases a Relatively Concentrated Landscape with top leaders such as Bovie Medical Corporation, Ethicon (J&J), Olympus Corporation, CONMED Corporation, and Medtronic amongst others holding a market share of approximately 45 percent. Technological innovations combined with strategic mergers and acquisitions aimed at expanding product portfolio and improve patient safety and procedure accuracy, are anticipated to remain the core differentiation strategies among surgical generators manufacturers. Moreover, FMI also foresees increased investments in research and development activities, generating significant demand for surgical generators, mostly in hospitals, as per the study.

For instance, Olympus, a key players in the global surgical generators market, introduced its ESG-300 Electrosurgery Generator. The Argon Plasma Unit (APU-300) including the Olympus exclusive Smart Argon mode identifies distance to tissue and regulates power automatically. US Medical Innovations, in 2017, launched its advanced Smart Electrosurgical Generator Canady Plasma offering Graphical Interface Management Surgical System and Tissue Impedance Sensitive Control.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-663

For a detailed analysis of the competition in surgical generators market along with assessment of all the segments and exclusive insights on the key dynamics shaping the surgical generators market at a global level.

Hypoparathyroidism Treatment Market to Witness Exponential Growth by 2026

The global hypoparathyroidism treatment landscape that only gained much significance post the FDA approval of Natpara in 2015, is projected grow at a rather robust CAGR of approximately 8% through 2026. As per a recent in-depth analysis by Future Market Insights (FMI), the valuation of global hypoparathyroidism treatment market is expected to stand at US$ 663.7 Million in 2019. Although the growth rate is expected to showcase similar trends, the global hypoparathyroidism treatment market is still in its infancy, with most of the treatment options in various phases of clinical programs.

“The global hypoparathyroidism treatment market holds the potential to exceed the US$ 1.1 Billion mark by 2026, in terms of revenue. The treatment landscape for hypoparathyroidism—a rare endocrine disorder, characterized by high phosphate and low calcium levels, during low or inappropriately normal PTH level—will mostly be driven by increasing incidences of thoracic surgeries and cancer combined with Rising screening rates of thyroid diseases. Moreover, considering the rarity, hypoparathyroidism was classified as an orphan disease in European Union and United States. Considering which, favorable government schemes relating to orphan drug combined with tax incentives such as tax credits for qualified clinical trials and market exclusivity upon regulatory approval are some expected to translate into high return on investment for companies innovating drugs in hypoparathyroidism treatment market”, explains a senior analyst.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-7857

A Comprehensive Analysis of the Pipeline Clinical Programs for Hypoparathyroidism Treatment by FMI, Reveals:

• There are around 47 ongoing clinical programs, globally, at different stages of development, wherein, 43 are interventional studies and 19 involve API with high potential market equity.
• Most of these clinical programs are aimed at evaluating the efficacy of different treatment lines for hypoparathyroidism treatment, involving Calcitriol, calcium supplements, and magnesium.
• Moreover, since hypoparathyroidism is the state of decreased secretion or activity of parathyroid hormone (PTH), close to 12 such clinical trials are focused on parathyroid hormone.
• Of the total active clinical programs, phase III and phase IV clinical trials, collectively account for approximately 37.3 percent.
• FMI, in its market study on hypoparathyroidism treatment also indicates that nearly 7 percent clinical programs stand terminated, suspended or withdrawn given their side-effects and failed efficacy.
• Although approximately 45 percent clinical trials stand completed, most of the trials do not meet or partially meet the hypoparathyroidism treatment guidelines set by regulatory authorities.
• Of the 47 percent active clinical trials, Shire continues to remain the leader in Hypoparathyroidism treatment clinical space with over 7 such active programs, followed by Entera Bio Ltd.
• North America, accounting for nearly 57 percent leads the clinical trials landscape for hypoparathyroidism treatment, followed by Europe at 29 percent, as in 2017.

Natpara Holds Approximately $2 Billion Market Opportunity, Reveals FMI

• Considering a significant patient pool for hypoparathyroidism treatment and extremely low competition, Natpara is projected to showcase maximum revenue opportunity, with its demand expanding at magnificent CAGR of 145.8 percent, in the last few years.
• Ever since its approval in 2015, Natpara has demonstrated a year-on-year growth of 72.8 percent through 2017
• Despite labeling restrictions (Natpara Risk Evaluation and Mitigation Strategy (REMS) Program), considering Natpara’s side effects including possible bone cancer (osteosarcoma) and high blood calcium (hypercalcemia), the U.S. currently accounts for 99 % of the total Natpara sales. In EU, sales of Natpara reached US$ 109.8 Million, in H1 2018—both the regions representing substantial revenue growth opportunities.
• The bioengineered replacement biologic is also projected to drive significnat adoption of drug titration based on individual cases, translating into personalized medicines.

Hypoparathyroidism Treatment Market Showcases a Fairly Consolidated Landscape

Largely dominated by branded drug manufacturers, the competition in Hypoparathyroidism Treatment Market is projected to remain low through the forecast period of 2018-2026. Key leaders including EnteraBio Ltd., Shire-NPS Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd. account for nearly 50 percent market share, with a key focus on developing novel treatment options for hypoparathyroidism. Apart from new product innovations, key players are also expected to take the ‘strategic acquisitions to expand global presence combined with increasing distribution channel’ route to reach untreated patient pool. In Asia, India accounts for the highest hypoparathyroidism-related mortality incidences, compared to any other region, arising from lack of sufficient screening and treatment lines. However, on the other hand, large unmet treatment needs combined with long clinical trials, will translate into patients opting for alternative medications available in the form of calcium and vitamin generics, thereby increasing the buyer advantage.

Insights Drawn From Segmentation Analysis of Hypoparathyroidism Treatment Market

• While US dominates the hypoparathyroidism treatment landscape with 86 percent market share considering reasons mentioned, Asia Pacific is also projected to witness strong growth.
• In terms of drug class, calcium supplements will remain the most preferred, with 38 percent market share. PTH will also showcase substantial growth rate.
• On the basis of route of administration, parenteral method will remain the fastest growth segment, compared to oral methods.
• Sales of hypoparathyroidism treatment drugs through retail pharmacies will generate maximum revenue, followed by hospital pharmacies.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-7857

Apart from pipeline and brand analysis, FMI in its comprehensive report on global hypoparathyroidism treatment, also offers actionable insights on the key market dynamics, pricing analysis, and opportunity assessment. 

The increasing screening rates as well as geriatric population are expected to be the critical drivers of the bronchoscopes market

As per its latest report, Bronchoscopes Market, the company has reported estimated steady increase in revenues derived from sales of bronchoscopes throughout the forecast period. Revenues from global bronchoscopes market is projected to expand at a CAGR of 4.3% over 2018-2028.  Growing population base aged over 65 years and rapid increase in incidence of pulmonary disorders are primary factors estimated to push market revenues across all regional markets. The global bronchoscopes market, though mature, exhibits an incremental opportunity US$ 224.3Mn over the forecast period. Bronchoscopy is an endoscopy technique, used to diagnose and treat respiratory diseases, thus helping the user to analyze the distal branches of the bronchi. Bronchoscopy procedure is done by a thin, lighted tube known as bronchoscopes, which is entered from the mouth and nose into the system. Bronchoscopes enables miniaturizing to the smallest point enhancing visualization. Availability of developed healthcare infrastructure is fuelling the adoption of bronchoscopes for pulmonary imaging purpose and quickening the diagnosis of diseases.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-7965

Most European countries and Japan are witnessing a rapid ageing in its population base. According to World Population Prospects-2017, the number of geriatric people (aged 60 +) is expected to be more than double (2.1 Bn) by 2050 and to more than triple (3.1 Bn) by 2100. This will increase application of bronchoscopes over the forecast period. According to Centers for Disease Control and Prevention, 3.5 million people in America have been recognized with a type of chronic obstructive pulmonary disorders, severe emphysema. It is seen that there is an increase in the incidence of respiratory disorders due to which demand of bronchoscopes is also increasing. It is seen that 500,000 bronchoscopy procedures are undertaken through bronchoscopes per year in the U.S. alone. There are several Bronchoscopes which are launched recently and has advance technology such as charge-coupled devices (CDD) due to which it is highly in demand by various end users such as hospitals. The Flexible Fiber Bronchoscopes is expected to hold the largest market share over the forecast period which indicates the high demand of the product throughout the forecast period. Bronchoscopes are also used to diagnose tumors, chronic cough, pulmonary infections, etc. Physicians also use bronchoscopes to deliver medication to patient’s lungs and/or remove objects that could be caught in airways.

Competition from alternative treatment methods and growing regulatory stringency concerning patient safety are factors dampening the revenue prospects of the bronchoscopes market. Physicians prefer flexible fiberoptic bronchoscopes because of improved patient comfort and reduced use of anesthesia.

The company has segmented the Bronchoscopes market into product type, modality, and end users. On the basis of product type, Video Bronchoscopes holds the highest revenue share due to application of advanced charge-coupled technology. On the basis of modality type, Flexible Fibre Bronchoscopes exhibits the highest market share in year 2018. On the basis of end user, Hospitals end user segment holds the highest revenue and market share in year 2018 which is followed by Outpatient Centres.

On the basis of region, Europe region is expected to account for the largest revenue share with US$ 131.1Mn in 2018 in bronchoscopes market. However, Asia Pacific Bronchoscopes market is expected to account for highest market share at the end of the forecast period due to increased adoption across healthcare facilities. Additionally, most key bronchoscopes manufacturers are focusing on the emerging markets such as Asia-Pacific due to large unmet needs in the region and thus manufacturers of bronchoscopes have better growth potential and scope of expanding their distribution channel in the region. Change in disease patterns triggered by rising luxury, changing lifestyle, raise in demand for quality healthcare & improved access to healthcare services make the emerging markets highly cost effective for the bronchoscopes manufacturing companies. Latin America and Middle East & Africa have the least lucrative bronchoscopy market.

Methodology With Latest Advancements and Application @ https://www.futuremarketinsights.com/askus/rep-gb-7965

The company’s report tracks some of the key companies operating in the Bronchoscopes market, such as Olympus Corporation, Fujifilm Holdings Corporation, Teleflex Incorporated, KARL STORZ GmbH & Co KG, Richard Wolf GmbH. HOYA Corporation. (Subs. PENTAX Medical), Ambu A/S, Shanghai AoHua Photoelectricity Endoscope Co., Ltd. Rochling Group.

The increasing screening rates as well as geriatric population are expected to be the critical drivers of the bronchoscopes market

The prevalence of obesity and cardiovascular diseases is increasing due to modern-day sedentary life style, which is projected to surge the growth of the point-of-care cholesterol monitoring device market. Physical inactivity is the vital cause of cardiovascular diseases. It is almost affecting every section of the society. Wide spread incidence of cardiovascular diseases is expected to increase the demand for point-of-care cholesterol monitoring devices. The rising demand for point-of-care cholesterol devices is further expected to create enormous growth opportunities for the manufactures operating in the point-of-care cholesterol monitoring device market. People now prefer self-testing and daily monitoring of the condition of a disease, which has increased the adoption of point-of-care cholesterol monitoring devices.

According to the World Health Organization (WHO), it is estimated that nearly 17.9 million people die due to cardiovascular diseases worldwide, which accounts for 31% of all the deaths worldwide. The growing incidence of cardiac arrest, high blood pressure and strokes is also a factor expected to surge the demand for point-of-care cholesterol monitoring devices.

For More Details, Request to View a Sample Copy of This Report @  https://www.futuremarketinsights.com/reports/sample/rep-gb-7773

Numerous awareness programs to control and prevent high cholesterol are organized by the governmental organizations these days. For instance, the National Heart Disease and Stroke Prevention Program and Lipid Standardization Program are conducted by CDC (Centre for Disease control and prevention) for creating awareness among population. These programs are conducting trainings and campaigns to spread awareness regarding the ill effects of cholesterol and they also are giving education to the staff of the hospitals. In the recent years, the trend of healthy living and eating has increased due to  various government initiatives such as campaigns leading  to higher adoption of the cholesterol self-testing devices resulting in  the growth of point-of-care cholesterol monitoring device market in the forecast period. It is reported by CDC (Center for Disease control and prevention) that more than half the U.S population, i.e., 55% of U.S adults are taking medication for cholesterol-related health problems. Thus, rising incidence of cardiovascular diseases and complications due to high cholesterol is projected to trigger the growth of the global point-of-care cholesterol monitoring device market.

Point-of-care monitoring devices are helpful in critical situations requiring rapid turn-around time of test results for clinical decision-making. But there are many challenges associated with POCT, mainly related to quality assurance. The tests performed in laboratories are carried out by trained professionals under GLP (Good lab practices) and certain measures are implemented for delivering acute results for patient safety.

The company has segmented the point-of-care cholesterol monitoring device market on the basis of product type, technology, application, end user and regions. Based on product type, the point-of-care cholesterol monitoring device market has been segmented into point-of-care instruments and testing kits. Testing kits segment is projected to hold large share in the point-of-care cholesterol monitoring device market. According to the company, the testing kits segment accounted for a revenue share of over 60% in the global point-of-care cholesterol monitoring device market in 2017.

Geographically, the global point-of-care cholesterol monitoring device market has been segmented across regions, namely North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding China & Japan, China, Japan and MEA. North America, followed by Asia Pacific, is expected to hold substantial revenue share in the global point-of-care cholesterol monitoring device market.  Many local players in Japan are focusing on increasing their market share in emerging regions such as MEA and APECJ.

Based on end users, the point-of-care cholesterol monitoring device market is segmented into hospitals, diagnostic centers & laboratory, ambulatory surgical center and home care sittings.  The diagnostic centre & laboratory segment is expected to hold large share in the point-of-care cholesterol monitoring device market.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-7773

The company’s report tracks some of the key companies operating in the point-of-care cholesterol monitoring device market, which include F. Hoffmann-La Roche Ltd., Acon Laboratories, Inc., Abaxis, Inc., Abbott Laboratories, SD Biosensor, Inc., Jant Pharmacal Corporation, DiaSys Diagnostic Systems GmbH, Bioptik Ltd., and Fitech UK Ltd., among others.

Airway Management Devices Market: Product Recalls and Safety Concerns to Restrict Revenue Growth

According to the latest research by the company, the global airway management devices market is expected to be valued at US$ 1,816.8 Mn, by 2028 end. The report on the airway management devices market further projects significant growth potential with average year-on-year growth rate pegged at 3.2% through 2028.

The high demand for airway management devices in anesthesia administration is the major factor expected to drive the growth of airway management devices market. Likewise, advancement in pediatric airway management devices is expected to favor the growth of the airway management devices market over the forecast period. Products such as ‘Classic laryngeal mask airway’ and ‘proseal LMA’ are gaining traction in the market for pediatric airway management. Classic LMA has 95–98% efficiency in achieving adequate ventilation in children. The key market players are focusing on making acquisitions and mergers with other players, which is expected to create lucrative growth opportunities for the manufacturers of airway management devices. In November 2015, Medtronic Plc. completed the acquisition of Aircraft Medical to expand the endotracheal tubes portfolio. Also, the growing adoption of disposable laryngeal masks in pre-hospital settings is also expected to favor the growth of the airway management devices market over the forecast period. The introduction of single/double-lumen endobronchial tube with camera is expected to create a growth opportunity for the airway management devices market. For instance, Ambu A/S offers VivaSight-DL double lumen tube with an integrated high-resolution camera, which makes placement of double lumen tube fast and effective. VivaSight-DL offers continuous visual monitoring throughout the procedure.

Read Comprehensive Overview with Sample of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7775

However, complications and limitations associated with airway management devices are expected to impact the growth of the airway management devices market. Moreover, product recalls and safety issues associated with airway management devices are the other factors that are expected to hamper the growth of the airway management devices market.

The company has segmented the global airway management devices market based on product type, usage type, end user and regions. Based on product type, the airway management devices market is segmented into laryngeal masks, tracheostomy tubes, endotracheal tubes, endobronchial tubes, nasal airway tubes, and oral airway tubes. The endobronchial tubes segment is expected to contribute high revenue share in global airway management devices market.

By usage type, the airway management devices market is segmented into single use/ disposable and reusable segment. The single use/disposable segment is expected to contribute high value share in the global airway management devices market. Based on end user, the airway management devices market is segmented into ambulatory surgical centers, hospitals and specialty clinics segment. In terms of revenue, the hospitals segment is projected to hold significant revenue share in the global airway management devices market over the forecast period.

On the basis of region, the global airway management devices market has been segmented into North America, Europe, Latin America, Asia Pacific (APAC) and the Middle East & Africa. North America is expected to contribute large revenue share in the global airway management devices market. The demand for airway management devices has increased in North America due to increasing number of surgical procedures in the U.S. as well as increasing healthcare expenditure. The Asia Pacific (APAC) is expected to witness high growth due to increasing per capita expenditure and number of laparoscopic procedures for respiratory disorders. Europe is expected to contribute second large revenue share in the global airway management devices market.

For more information, and to download the report, please: https://www.futuremarketinsights.com/askus/rep-gb-7775

The report tracks some of the key companies operating in the global airway management devices market. Representative players included in the report are Medtronic Plc., Cook Medical Inc., Teleflex Incorporated, Smiths Group Plc. Ambu A/S, Intersurgical Ltd, VBM Medizintechnik GmbH., SunMed, Vyaire Medical Inc., Karl Storz SE & Co. KG and others. Manufacturers are focusing on the development of airway management devices to diminish associated complications and limitations, which will create enormous growth opportunities for them over the forecast period.

Angio Suites Market: Rising Prevalence of Cardiovascular Diseases

Over the past few years, it is observed that healthcare spending has grown tremulously across the globe. The per capita healthcare expenditure is presently following a growing trend across the globe. The healthcare industry accounts for around 10% of the world GDP. According to the IMF, the healthcare spending is expected to upsurge by over 6% yearly, based on the current GDP forecast. Increasing healthcare spending is showing improvements in the healthcare setting as a whole. Increase in the budgets of hospitals would specify the use of better quality equipment. This is further expected to drive the growth of the angio suites market.

According to the latest research by the company, the global angio suites market is expected to account for over US$ 3,100.0 Mn in terms of value by the end of 2028. The market is expected to exhibit significant growth potential with an average Y-o-Y growth rate of 6.0% through 2028.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7758

Rising geriatric population with the prevalence of heart diseases globally is leading to an increase in the demand for angio suites, which is expected to propel the market scope over the long run. The number of U.S. population aged 65 and older is projected to be more than double, i.e., from 46 million to 98 million by 2060. According to the CDC, around 610,000 people die due to heart diseases in the U.S. every year.

Furthermore, increase in the number of healthcare facilities and medical infrastructure in emerging regions is expected to boost the demand for better healthcare services and products, which is, in turn, expected to create demand for angio suites in the market. This is expected to boost the global angio suites market.

However, the dearth of trained healthcare professionals and low awareness among medical facility are expected to hamper the growth of the global angio suites market. Globally, the demand for angio suites is increasing, however, due to the limited number of skilled operators and professionals, the growth of the market is expected to be stagnant. Medical faculty at the majority of government-run and private hospitals in India have no or low awareness regarding the latest technologically advanced devices. These factors are majorly responsible for hampering the growth of the global angio suites market. Furthermore, the high cost involved in the initial set up and installation of advanced angio suites and broadband technology in remote locations is one of the factors expected to hamper the growth of the angio suites market.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-7758

Challenges related to healthcare are improving as the economic conditions are improving in developing countries, such as China and India. Similar to the markets in China and India, companies are focusing on creating a base of documented local evidence. This has been aiding healthcare professi onals to validate and exemplify the value of diagnosis through relevant evidence and results from their own countries.

According to the company, the single plane angio suites segment accounted for a revenue share of over 65% in the overall angio suites market in 2017. However, the growing popularity of alternative treatment devices is likely to limit the growth of the market in the near future. The Asia Pacific angio suites market is expected to register high CAGR in the global angio suites market during the forecast period.

The company has segmented the global angio suites market into biplane angio suites and single plane angio suites. In terms of revenue, the single plane angio suites segment is expected to hold maximum revenue share over the forecast period.

Browse Full Report Now @ https://www.futuremarketinsights.com/reports/angio-suites-market

The company’s report tracks some of the key companies operating in the angio suites market, which include GE Healthcare, Koninklijke Philips N.V., Siemens AG, Shimadzu Corporation, Canon, Inc., and others. The key players in the market are focused on increasing product footprint to strengthen their position in the market and also to expand their product penetration in the emerging markets.

Increasing Adoption of Programmable and Anti-siphon Shunt Valves to Foster Growth of the Hydrocephalus Shunt Market

According to the latest research by the company, the global hydrocephalus shunt market is expected to be valued at US$ 599.7 Mn, by 2028 end. The report on the hydrocephalus shunt market further projects significant growth potential with average year-on-year growth rate pegged at 2.3% through 2028.

The growing incidence of hydrocephalus due to increasing number of accident cases is the major factor expected to drive the growth hydrocephalus shunt market. Various private and government organizations are focusing on spreading awareness regarding hydrocephalus, which is also expected to favor the growth of the hydrocephalus shunt market over the forecast period. Half of the patients experience complications such as shunt blockage and drainage program and need shunt revision post hydrocephalus shunt revision surgery.

According to the UK Shunt Registry, around 3,000 shunt operations are performed in the U.K. every year: 1660 pediatric (33.5% primary and 66.5% revisions) and 1400 adult (53% primary and 47% revisions). Increasing adoption of magnetically programmable valve over fixed pressure valves favors the growth of the market. Moreover, availability of MRI-compatible programmable hydrocephalus valves is also expected to propel the growth of the hydrocephalus shunt market. These programmable hydrocephalus valves are suitable for up to magnetic field interaction at 3 Tesla or less when the specific guidelines are followed. Moreover, anti-siphon devices are gaining traction to avoid siphon effect namely over drainage of cerebrospinal fluid. Moreover, strong reimbursement policies for hydrocephalus diagnosis and treatment are expected to boost the growth of the hydrocephalus shunt market.

Request Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7756

However, stringent regulatory policies for approval of hydrocephalus is expected to considerably impact the growth of the hydrocephalus shunt market. Moreover, risks and complications associated with shunt implant is the other factor expected to hamper the growth of the hydrocephalus shunt market. Besides, the high cost of surgery and lack of neurologists are the major challenges in the growth of the hydrocephalus shunt market.

The company has segmented the global hydrocephalus shunt market based on product type, procedure type, age group, and regions. Based on product type, the hydrocephalus shunt market is segmented into hydrocephalus valves and hydrocephalus catheters. The hydrocephalus valves segment is expected to represent the high revenue share in the hydrocephalus shunt market due to increasing adoption of adjustable pressure valves. By procedure type, the hydrocephalus shunt market is segmented into ventriculoperitoneal, ventriculoatrial, lumboperitoneal and ventriculopleural. The ventriculoperitoneal segment is expected to contribute high value share in the global hydrocephalus shunt market. Other procedures are performed when the complication is associated with ventriculoperitoneal procedure or risk of infection peritoneal region. Based on the age group, the hydrocephalus shunt market is segmented into pediatric and adult segment.  In terms of revenue, the pediatric segment is projected to hold significant revenue share in the global hydrocephalus shunt market over the forecast period as a large number of revision surgeries are performed among pediatric patients.

On the basis of region, the global hydrocephalus shunt market has been segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding China & Japan, China, Japan, and the Middle East & Africa. North America is expected to contribute large revenue share in the global hydrocephalus shunt market. The demand for hydrocephalus shunt has increased in North America, as the prevalence of hydrocephalus is high in the U.S. as well as due to increasing healthcare expenditure. The Asia Pacific excluding China and Japan is expected to witness the high growth due to increasing government funding and support for hydrocephalus treatment. Western Europe is expected to contribute second large share in the global hydrocephalus shunt market due to favorable reimbursement policies and adoption of advance surgical methods.

Request to Browse Report Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-7756

The report tracks some of the key companies operating in the global hydrocephalus shunt market. Representative players included in the report are Medtronic Plc., B. Braun Melsungen AG, Integra LifeSciences Corporation, Natus Medical Incorporated, Tokibo Co., Ltd. (Sophysa SA), Christoph Miethke GmbH & Co. KG and others. Manufacturers are focusing on the development of new shunt valves to diminish complications and risk associated with the shunt, which will create enormous growth opportunities for them over the forecast period.

Increasing Demand for Endodontics and Orthodontics Due to Increasing Oral Diseases and Dental Caries

According to the World Health Organization (WHO), oral diseases are the fourth-most expensive diseases to treat in developed as well as developing countries. Dental caries is one of the main oral health problems in a majority of th industrialized countries. Endodontic and orthodontics products are used for these problem, and both are a branch of dentistry that focus on diagnosing tooth pain, performing root canal treatment, and correcting teeth and jaws that are positioned improperly.

The growing prevalence of dental caries among children up to 12 years of age, and the rising incidences of oral diseases promote the demand for dental caries, which includes endodontic and orthodontics products. An increasing number of qualified dental professionals, worldwide, would increase access to dental care products, which include endodontic and orthodontics products. These products are expected to trigger the growth of the global endodontic and orthodontics market over the forecast period.

Consumer are assumed to demand dental services for satisfaction-yielding attributes embodied in them. Increasing awareness towards different treatment options for dental caries has led to the growing demand for dental consumables in endodontic and orthodontics market. The number of people reporting to dentists for routine dental checkups is increasing, and a regular visit to the dentist is becoming a part of lifestyle practices. In countries such as China and Australia, people are giving more importance to the aesthetic aspects of dental products, which is expected to boost the orthodontics and endodontic market over the forecast period. Increasing consumer preference for discounted products. The discount products is growing at the cost of the premium segment of orthodontics and endodontic. Dental services are not covered under public insurance. Thus, the orthodontics and endodontic market entirely follows the consumer perception of dental health.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7753

A majority of dental hospitals in China have online appointment systems. Healthcare-related mobile apps such as Practo help patients find dentists near them, and allow them to book an online appointment. The growing dental care industry is expected to be another factor driving the growth of the endodontic and orthodontics market.

Increasing trade of endodontic and orthodontics, dental materials, supplies, and consumables in many countries is expected to boost the growth of the endodontic and orthodontics market. Moreover, increasing awareness towards oral hygiene is expected to drive the growth of the endodontic and orthodontics market.

Upper middle-class population is purchasing more than single dental coverage policies in order to fill the gap between cost of dental restoration and reconstruction services and amount reimbursable by public healthcare policies.

With the increasing presence of private dental insurance subscriptions, small group practices have started. Consolidation of the dental industry has led to the lowering of the out-of-pocket cost for dental services, due to the implementation of Protection and Affordable Care Act (PPACA) in the U.S. The rising disposable income of the middle-class population across the globe also has led to changing customer approach towards dental caries treatment.

The endodontic and orthodontics market is segmented on the basis of product and end user.

Based on product type, the endodontic and orthodontics market is segmented into endodontic and orthodontics products. Based on endodontic products, the endodontic and orthodontics market is segmented into permanent sealers, files, obturation devices, and others. Based on orthodontics product, the endodontic and orthodontics market is segmented into dental braces, molar bands, wires, retainers, and others. Based on end user, the endodontic and orthodontics market is segmented into dental laboratories, dental hospitals, dental clinics, and others.

In terms of revenue, the endodontic type segment in the endodontic and orthodontics market is expected to hold significant share over the forecast period. In the end user segment of endodontic and orthodontics market, dental laboratories, dental hospitals, dental clinics, and others in the endodontic and orthodontics market are expected to exhibit limited investment opportunities in terms of revenue through 2028.

Methodology With Latest Advancements and Application @ https://www.futuremarketinsights.com/askus/rep-gb-7753

Endodontic and orthodontics market report tracks some of the key companies operating in the endodontic and orthodontics market, such as Dentsply Sirona, Inc., 3M, Align Technology, Inc, DENTAURUM GmbH & Co. KG, FKG Dentaire SA, Ivoclar Vivadent Inc, Patterson Companies, Inc., Mani, Inc., Coltene Holding AG, Micro Mega SA, and Danaher Corporation, among others.

Reduced Risk of Stroke and Atrial Fibrillation upon Use of Left Atrial Appendage Closure Device

The rising awareness regarding the side effects caused by anticoagulant drugs is expected to boost the demand for mechanical left atrial appendage closure devices in the appendage management market. According to the latest research by the company, the global appendage management market is projected to account for over US$ 352.5 Mn, in terms of value, by 2028 end. The report on the appendage management market further projects significant growth potential with average year-on-year growth rate pegged at 6.7% through 2028.

About 33.5 million people suffer from atrial fibrillation and according to the Centers for Disease Control and Prevention, approximately 130,000 patients suffering from atrial fibrillation die each year in the U.S. Atrial fibrillation increases the risk of stroke by five-fold and majority of individuals suffering from atrial fibrillation are aged 65 years and above. The appendage management market is categorized into epicardial and endocardial LAA closure devices for appendage management. The appendage management market is dominated by endocardial LAA closure device as epicardial LAA closure device is an emerging and a relatively new approach. Endocardial LAA closure devices segment contributes two-third of the total appendage management market share and is expected to continue to do so over the forecast period. Epicardial LAA closure devices segment in the appendage management market is expected to grow by 7.2% CAGR during the forecast period owing to their growing adoption and less complications associated with implantation of epicardial LAA closure devices as compared to endocardial LAA closure devices.

Request Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7752

LAA closure devices in the appendage management market are highly adopted in catheterization laboratories owing to the specialized function performed by the device, which can be efficiently implanted in the catheterization laboratories. Catheterization laboratories are specialized in diagnosis and treatment of problems, abnormalities and complications related to arteries and the chambers of the heart and play a vital role in the growth of the appendage management market. Moreover, the stent procedure used in implantation of the LAA closure devices is efficiently performed in catheterization laboratories contributing to the growth of the appendage management market. However, the growing popularity of LAA closure devices and their crossover success in clinical studies for safe and efficient occlusion of the left atrial appendage have increased their implementation in hospitals. Easy implantation features, advancing navigation and visualization technology and availability of products assisting in the implantation of LAA closure devices are further expected to contribute to the growing adoption of LAA closure devices by hospitals.

Owing to the presence of key players and higher healthcare expenditure, North America is projected to be the dominant region in the global appendage management market. Furthermore, the growing awareness amongst general population about atrial fibrillation and treatment against it as a precaution for heart stroke adds to the supremacy of the North America appendage management market. Europe is projected to be the prominent region in the global appendage management due to similar reasons. The Europe appendage management market is estimated to create incremental opportunity worth approximately US$ 49.0 Mn between 2018 and 2028. MEA is forecasted to behold high CAGR and potential to create a considerable revenue share in the global appendage management market. Regional penetration of manufactures and increased availability of LAA closure devices are likely to boost the growth of the appendage managements market in the MEA.

The company has segmented the global appendage management market based on product type, end user and region. In terms of revenue, the endocardial LAA closure device product type segment is expected to hold significant share over the forecast period. Additionally, the hospital end-use segment in the appendage management market is predicted to exhibit growth by 8.0% CAGR during the forecast period.

Methodology With Latest Advancements and Application @ https://www.futuremarketinsights.com/askus/rep-gb-7752

The report tracks some of the key companies operating in the appendage managements market, including Johnson & Johnson Services, Inc., Cardia, Inc., Abbott Laboratories, LifeTech Scientific Co., Ltd, Medtronic plc., SentreHEART, Inc., Boston Scientific Corporation, Occlutech International AB, AtriCure, Inc., etc.

Homecare Dermatology Energy-based Devices Market: Rising prevalence of skin problems has been leading to scarring

Fast-track FDA approvals play a vital role in new product launches, especially in the LED and lasers categories, according to a new FMI study.

Growing commercialization of advanced technology in homecare dermatology and frequent introduction of user-friendly dermatology services are collectively boosting the growth prospects for homecare dermatology energy-based devices landscape at a global level.

According to a newly released intelligence report by Future Market Insights, exhibiting nearly 5% year over year growth in revenue, the global homecare dermatology energy-based devices landscape is likely to be worth over US$ 550 Mn in 2020. While maximum incremental opportunity is projected for China and APEC, North America – despite being the global leader – is likely to witness moderate growth in coming years.

Rapidly growing demand for homecare devices as a result of a paradigm shift from conventional clinics to in-house, non-invasive energy treatments is prominently responsible for healthy revenue growth projections for homecare dermatology energy-based devices.

Technological advancements in these devices are widening their application base, thereby pushing the rate of adoption further at a global level. Another strong push factor associated with homecare dermatology energy-based devices includes their availability as the OTC products.

• Product type analysis of market landscape reveals that laser and IPL (intense pulsed light) equipment are enjoying the highest sales, whereas LED equipment is projected to emerge as the most attractive segment in homecare dermatology energy based devices space in the near future.
• Hair removal and acne, followed by wrinkles treatment, are reportedly the most extensively sought after applications of homecare dermatology energy based devices.
• E-commerce dominates all other distribution channels, according to the report. Hyper markets and super markets also remain among the preferred channels for product distribution.

Do Inquiry to Get the Sample of Report Here @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7699 

A Bird’s Eye View of the Global Landscape

“The global market for homecare dermatology energy based devices is a highly consolidated landscape, wherein the top two players collectively account for around 60% share of the market revenue. Koninklijke Philips, with more than a third of the market value share, secures the top position with its extensive portfolio of intense pulsed light devices used for hair removal,” explains a senior research analyst while offering the inclusions of the company’s recent report on the global homecare dermatology energy based devices market.

Adding further to the information about the market competition, the analyst says, “A majority of companies are prioritizing product innovations in LED, IR, and lasers segments. Moreover, a large number of market players are taking efforts for extended product reach through retail partnerships, in addition to NPD for a wider application base. Companies are also observed to be focusing on collaborations and acquisitions to reshape their product distribution strategy for better profitability”.

FDA Approvals Are Relatively Easy

Relatively easy and faster FDA approvals for homecare dermatology energy based devices are driving improved appearance of these devices in tandem with the latest handheld gadgets, which prominently curtail the need for frequent visits to professional cosmetic treatment centers.

A recent example includes FDA clearance for Titan – the anti-aging device launched by Skinovations Inc. later in 2017.

On a similar line, North American and European markets for homecare dermatology energy based devices are witnessing remarkable adoption in recent years. FMI identifies a slew of business expansion opportunities in the aforementioned regions for manufacturers of homecare dermatology energy based devices.

Moreover, growing R&D efforts as manufacturers in the US zoom in on the production quality, is likely to shape the performance of North America’s market for homecare dermatology energy based devices.

Methodology With Latest Advancements and Application @ https://www.futuremarketinsights.com/askus/rep-gb-7699 

Combination of Technologies for Better Treatment Output

Making the most of the best attributes of LED and lasers technologies, a new trend among manufacturers now involves the combination of both the technologies for manufacturing homecare dermatology energy based devices. While these devices are claimed to be effectively reducing fine lines and improving skin tone with LED, lasers enable them to be highly target specific. A recent example is of YA-MAN’s RF Beaute Photo PLUS.

Trend Analysis of Endoscopy Fluid Management Systems 2019

Laparoscopy Suction Irrigation Pumps are likely to remain the top selling product type, whereas developing economies are projected to demonstrate impressive revenue growth in coming years.

Providing a brief overview of the FDA regulations for Class II medical devices such as endoscopes, a new study presented by Future Market Insights offers an exhaustive assessment of the global endoscopy fluid management systems landscape for a 10-year projection period, 2018-2028.

According to the FMI study, as the Tier 1 players continue to contribute over 70% share of the market revenue, the global endoscopy fluid management systems landscape remains a highly consolidated space.

The report covers extensive profiling of the top four performers including a few of the biggest industry names such as Stryker Corporation and Olympus Corporation. However, research indicates that even local players have strong penetration in regional markets.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-4358

Top 3 Insights from Key Players Analysis

• While a majority of companies are focusing on new product launches, strategic mergers and acquisitions are likely to emerge the most profitable developmental decisions in the near future.
• Most of these strategic moves will be primarily directed to address the high price point pressure associated with endoscopy fluid management systems that often affects revenue growth in developing economies.
• Major hospital networks in developed regional markets are witnessing M&A between hospitals, which is likely to shape costing of medical devices such as endoscopy fluid management systems – eventually slashing down the profitability margins of manufacturers.

“Constantly increasing chronic disease instances, coupled with immense technological advances in the field of endoscopy, is prominently driving the US$ 342 Million market for endoscopy fluid management systems (or irrigation pumps) in recent years,” says a senior research analyst at the company.

Top 5 Insights from Segmental Analysis

• With maximum use in laparoscopic procedures, endoscopy fluid management systems continue to register maximum revenue generation through sales of laparoscopy suction irrigation pumps, followed by laparoscopy fluid management systems.
• Based on the modality of endoscopy fluid management systems, the Benchtop holds a substantial market value share.
• Hospitals register the highest consumption of endoscopy fluid management systems.
• Owing to a massive number of cancer survivors in the US, North America’s market for endoscopy fluid management systems is currently accounting for the largest revenue share in the global landscape, followed by Asia Pacific and Europe.
• MEA and Latin America are likely to represent a significant incremental opportunity, according to FMI study.

Healthy Year over Year Revenue Growth Projected for Asia Pacific

APAC has become the hotspot for leading medical device companies, which is further intensified by dramatically growing medical tourism sector. Across APAC, Japan is likely to account for substantial revenue generation, enabling the regional market secure second spot in the global endoscopy fluid management systems landscape. FMI projects over 7% year on year revenue growth in 2020 and beyond, for this regional market.

Government Regulations Favor Market Growth in Latin America

Latin American market for endoscopy fluid management systems is thriving at a promising pace owing to favorable government initiatives regarding endoscopic procedures and medical device marketing. Noteworthy demand for laparoscopy suction irrigation pumps within the region is identified to be responsible for the rapid revenue growth of endoscopy fluid management systems marketplace across Latin America.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-4358

Egypt’s End Users Drive Market Growth in MEA

The market for endoscopy fluid management systems in MEA is prominently driven by the improving regulatory landscape related to the marketing of medical devices, pushed further by impressive sales of laparoscopy suction irrigation pump based endoscopy fluid management systems. FMI spots higher market attractiveness in Egypt owing to the presence of a large number of end users. However, poor operational environment still remains a major growth barrier for the region.

Increase in the prescription of sleep aids is expected to boost the market of narcolepsy treatment globally

Revenue from narcolepsy treatment, globally is projected to stand at a valuation of US$ 3,818 Mn, registering an annual growth rate of 5.7 percent, from 2018-2028. Future Market Insights (FMI), in its newly published market intelligence outlook, highlights substantial demand for narcolepsy treatment in North America. Narcolepsy treatment landscape in Europe, will witness significant revenue growth given the rising affinity toward adoption of prescription treatments and adherence to the same on a long term basis.

Asia Pacific among other emerging economies including MEA and Latin America, on the other hand, are expected to showcase positive trends towards the adoption of narcolepsy treatment, due to:

• Strong distribution pipeline of the narcolepsy drugs.
• Emerging global and local biopharmaceutical companies.
• Increasing incidences of Obstructive Sleep Apnea (OSA) in Latin America. Obesity is reported to be the most common risk factor.
• Prevalence of moderately severe sleep apnea is estimated to be around 5% in women and 10% in men in South Africa. It is estimated that up to 90% of patients are undiagnosed.
• Prevalence of sleep apnea is more severe in the developing countries due to the lack of skilled physicians

In term of key forward market strategies, the primary objective manufacturers in the narcolepsy treatment market is to expand their footprint in the various regional markets, in order to solidify their market position.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7641 

Key Findings from the Regional and Competitive Landscape Analysis of Narcolepsy Treatment Market

• Leading narcolepsy treatment manufacturers are prioritizing regional-specific product development. The product portfolio expansion is mostly targeted in Asia Pacific.
• Apart from new product development—mostly arising from the presence of low cost generic versions of patented drugs, strategic partnerships and acquisitions with pave way for further business expansions.
• Manufacturers in the global narcolepsy treatment are also focused towards introducing new research and development units in different geographic regions.
• Industry leaders are focusing on maintaining long-term partnerships with pharmacies- in hospital and retail, drug stores, and e-commerce. Sales through e-commerce distribution channel is expected to contribute a significant revenue share in the global narcolepsy treatment market.
• FMI, has also noted an increasing focus on reformulation of well-known products and combinations, by manufacturers in North America in order to achieve higher sales and wide penetration.

There is a conscious shift from OTC medication to devices treating narcolepsy, driving significant revenue growth for the devices segment compared to drugs.  Growing incidences of inappropriate medication and addiction, translating into severe side effects including headache, prolonged drowsiness, daytime memory and performance problems, allergic reactions, and death in some cases, is the key driving factor. These side effects are associated with OTC as well as prescription-based sleep aids. Growing demand to treat narcolepsy with BiPAP is expected to push this segment of devices—predicted to expand at the highest CAGR. Moreover, devices in portable and available-for-rent formats, will translate into higher adoption rates, throughout the forecast period. Portable Continuous positive airway pressure (CPAP) devices are lighter and smaller and can also be used as a home based unit, further reducing the dependency on OTC pills and prescription drugs.

While explaining the growth trajectory of narcolepsy treatment market, a senior analyst from the healthcare domain underscores growing healthcare expenditure and rising incidence cases of fracture fixation and orthopedic disorders as key factors contributing to the demand of narcolepsy treatment though 2028. “Regulatory impositions by various global authorities including the FDA and European Commission along with currency fluctuations, regulations and changing taxation policies are some high-impact factors pushing the global demand for narcolepsy treatment”, the analyst further explains.

Need more information about Report methodology ? @ https://www.futuremarketinsights.com/askus/rep-gb-7641 

Critical Market Restrainers

Although the narcolepsy market is expanding at a robust CAGR, long waiting time for sleep services, lack of awareness and delayed diagnosis, severe side effects of sleep aids medication, lack of proper documentation for the usage and licensing of sleeping pills, and improper equipment regulations are some critical factors projected to restrain the growth of narcolepsy treatment market.